A role for oligonucleotide-based RNA-knock down technologies in functional genomics.
Functional genomics is inundating the pharmaceutical industry with large numbers of potential gene targets from several sources such as gene expression profiling experiments (DNA microchips, proteomics) or database mining. Oligonucleotide-based RNA-knock down technologies such as antisense or RNA interference can aid in the filtering and prioritization of target candidates in the drug discovery process.
Dorn
Gabriele
G
Functional Genomics, Novartis Pharma AG, Basel, Switzerland.
Hall
Jonathan
J
Hüsken
Dieter
D
Lange
Jörg
J
Martin
Pierre
P
Natt
Francois
F
Wishart
William L
WL
Weiler
Jan
J
D004345:Drug Industry / Q000379:methods; D023281:Genomics; D020411:Oligonucleotide Array Sequence Analysis; D009843:Oligoribonucleotides / Q000138:chemical synthesis*; D012313:RNA / Q000235:genetics; D034741:RNA, Small Interfering / Q000737:chemistry / Q000235:genetics
D009843:Oligoribonucleotides; D034741:RNA, Small Interfering; D012313:RNA